clinical trial · NCT05067283
A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)
Merck Sharp & Dohme LLC·phase1·recruiting·n = 830
Advanced Solid TumorsCalderasibPembrolizumabcarboplatinpemetrexedcetuximaboxaliplatinleucovorin5-fluorouracil
brief summary
This is a study evaluating the safety, pharmacokinetics, and efficacy of calderasib alone, and calderasib plus other combination therapies in participants with advanced solid tumors with identified kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation.
started
Dec 17, 2021
primary completion
Feb 25, 2030
completion
Feb 25, 2030
last updated
May 4, 2026
official title
A Phase 1, Open-label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and as Part of Various Combination Therapies in Participants With KRAS G12C Mutant Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol